EH3
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. … Read more
EH3 (EH3) - Total Liabilities
Latest total liabilities as of September 2025: €200.92 Million EUR
Based on the latest financial reports, EH3 (EH3) has total liabilities worth €200.92 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EH3 - Total Liabilities Trend (2021–2024)
This chart illustrates how EH3's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
EH3 Competitors by Total Liabilities
The table below lists competitors of EH3 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Villeroy und Boch AG Pfd.
LSE:0OPA
|
UK | €1.39 Billion |
|
Docebo Inc
NASDAQ:DCBO
|
USA | $132.31 Million |
|
Zhejiang Dilong New Material Co Ltd
SHE:002247
|
China | CN¥281.35 Million |
|
WAAREE RENEWABLE TECHNOLOGIES LTD
NSE:WAAREERTL
|
India | ₹7.94 Billion |
|
Egis Technology
TWO:6462
|
Taiwan | NT$6.65 Billion |
|
Candel Therapeutics Inc
NASDAQ:CADL
|
USA | $13.47 Million |
|
PetroTal Corp
OTCQX:PTALF
|
USA | $291.98 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down EH3's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EH3's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EH3 (2021–2024)
The table below shows the annual total liabilities of EH3 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €199.17 Million | -28.76% |
| 2023-12-31 | €279.59 Million | -3.87% |
| 2022-12-31 | €290.85 Million | -27.46% |
| 2021-12-31 | €400.97 Million | -- |